RUA Life Sciences (RUA) AI Stock Analysis

• Market Cap: £7.14M
• Dividend Yield: N/A
• Average Volume (3M): 176.74K
• Price to Earnings (P/E): 1150.0
• Beta (1Y): 0.18
• Revenue Growth: 87.72%
• EPS Growth: N/A
• Country: UK
• Employees: 40
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Devices
• EPS (TTM): -0.01
• Shares Outstanding: 62,060,272
• 10 Day Avg. Volume: 89,142
• 30 Day Avg. Volume: 176,738
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: £11.50
• Price Target Upside: 0.00%
• Rating Consensus: Hold
• Number of Analyst Covering: 1

• Rating: 53 Neutral
• Price Target: 11.50p ▲(0.00% Upside)

RUA Life Sciences faces significant challenges with profitability and cash flow, despite strong revenue growth and a stable balance sheet. The technical indicators suggest a bearish trend, and the high P/E ratio indicates potential overvaluation. These factors collectively result in a moderate overall stock score.

RUA Life Sciences Business Overview & Revenue Model

Company Description

RUA Life Sciences (RUA) is a biotechnology company specializing in the development and commercialization of advanced materials for use in the medical sector, particularly in surgical implants and devices. The company focuses on innovative polymer technologies and regenerative medicine, aiming to improve patient outcomes through its core products, which include bioresorbable scaffolds and tissue-engineered solutions.

How the Company Makes Money

RUA makes money primarily through the sale of its medical products and technologies. Its revenue model includes direct sales to healthcare providers and hospitals, as well as partnerships with larger medical device companies for co-development and distribution of its products. Key revenue streams are driven by the licensing of its proprietary technologies, sales of surgical implants, and ongoing contracts for research and development with various medical institutions. Additionally, RUA may benefit from funding and grants aimed at advancing healthcare innovations, which further contribute to its earnings.

RUA Life Sciences Financial Statement Overview

Summary

RUA Life Sciences shows moderate revenue growth, but struggles with profitability and cash flow. The balance sheet is strong with low leverage, providing financial stability. However, persistent operating losses and negative cash flows are major concerns.

Income Statement

RUA Life Sciences has shown moderate revenue growth, with a 0.55% increase from 2023 to 2024. However, profitability remains a concern, as evidenced by persistent negative EBIT and net profit margins. Gross profit margins have improved to 78.33% for 2024, indicating cost management; however, the overall financial performance is weakened by substantial operating losses.

Balance Sheet

The balance sheet shows a stable financial position with a strong equity base and low debt levels. The debt-to-equity ratio is low at 0.05, indicating minimal leverage. However, the company has not been able to turn equity into positive returns, as reflected by negative ROE. The equity ratio stands at 87.93%, demonstrating a solid equity position.

Cash Flow

Cash flow analysis reveals challenges, with negative operating and free cash flows. The operating cash flow to net income ratio is less than optimal, highlighting cash flow issues. Free cash flow has improved slightly from the previous year but remains negative, indicating ongoing liquidity pressures.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	2.92M	4.11M	2.19M	2.18M	1.63M	1.53M
Gross Profit	2.19M	3.17M	1.72M	1.43M	1.04M	980.00K
EBITDA	445.00K	401.00K	-1.57M	-1.95M	-2.04M	-1.28M
Net Income	206.00K	1.00K	-1.44M	-2.00M	-2.07M	-1.45M
Balance Sheet
Total Assets	9.81M	9.26M	8.17M	5.66M	7.63M	10.15M
Cash, Cash Equivalents and Short-Term Investments	3.78M	3.57M	3.93M	1.48M	2.96M	6.29M
Total Debt	1.18M	1.03M	389.00K	475.00K	344.00K	410.00K
Total Liabilities	1.82M	1.86M	987.00K	980.00K	1.04M	1.65M
Stockholders Equity	7.86M	7.30M	7.18M	4.68M	6.58M	8.51M
Cash Flow
Free Cash Flow	-712.00K	-281.00K	-1.38M	-1.62M	-3.27M	-2.04M
Operating Cash Flow	-664.00K	-219.00K	-1.33M	-1.17M	-2.36M	-1.42M
Investing Cash Flow	151.00K	70.00K	-85.00K	-449.00K	-904.00K	-943.00K
Financing Cash Flow	3.85M	-196.00K	3.89M	132.00K	-66.00K	6.68M

RUA Life Sciences Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 11.50
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For GB:RUA, the sentiment is Neutral. The current price of 11.5 is above the 20-day moving average (MA) of 11.31, below the 50-day MA of 11.55, and below the 200-day MA of 11.98, indicating a neutral trend. The MACD of 0.03 indicates Negative momentum. The RSI at 54.57 is Neutral, neither overbought nor oversold. The STOCH value of 54.61 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for GB:RUA.

RUA Life Sciences Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
RUA	53 Neutral	£7.14M	1,150.00	0.08%	―	87.72%	―
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
IHC	45 Neutral	£18.38M	―	-51.63%	―	31.78%	10.27%
SUN	45 Neutral	£5.36M	―	-15.46%	―	-4.98%	-114.29%
OBD	44 Neutral	£11.55M	―	-333.59%	―	45.22%	55.71%

RUA Life Sciences Corporate Events

RUA Life Sciences Reports Robust Revenue Growth and Strategic Expansion

RUA Life Sciences has reported significant revenue growth for the fiscal year ending March 31, 2025, with an 86% increase to £4.1 million, driven by strong underlying business performance and the acquisition of the Abiss Group. The company has successfully reduced costs and improved cash control, resulting in an expected EBITDA of £0.3 million, a turnaround from the previous year’s loss. The company is focusing on expanding its contract manufacturing business and exploring new opportunities with its unique IP, particularly in combining textiles expertise with Elast-Eon. The acquisition of Abiss is expected to be beneficial despite an initial period of reduced orders due to excess inventory. Structural changes in the market are anticipated to positively impact Abiss, and RUA is exploring new licensing opportunities for Elast-Eon in various therapeutic areas.

Spark’s Take on GB:RUA Stock

According to Spark, TipRanks’ AI Analyst, GB:RUA is a Neutral.

RUA Life Sciences faces significant operational challenges with negative profitability and cash flow, despite a strong balance sheet. Technical indicators suggest a bearish trend, while the high P/E ratio indicates potential overvaluation. However, positive corporate developments, such as the CEO’s confidence and subsidiary turnaround, offer some optimistic signals for future growth.

To see Spark’s full report on GB:RUA stock, click here.